Ionis Pharmaceuticals shares tumbled nearly 29% in two days after a failed heart drug trial and a partner’s exit from Huntington’s disease programs, raising questions about future growth and competition in the biotech sector
Biotech investors are no strangers to volatility, but the past week delivered a sharp reminder of just how quickly fortunes can shift. Ionis Pharmaceuticals saw its stock price drop nearly 29% over five trading sessions in July after two major setbacks hit its drug development pipeline in rapid succession. The first blow came on July 9, when Ionis and its partner AstraZeneca announced that their heart drug Wainua failed to meet the primary endpoint in a late-stage trial for ATTR-CM, a rare but increasingly targeted form of heart disease. The following day, Roche ended two Huntington’s disease programs with Ionis, including the high-profile antisense drug tominersen, after disappointing trial results and safety concerns in animal studies.
Pipeline Pressure
The Wainua trial, known as CARDIO-TTRansform, was designed to test whether adding Wainua to standard care could reduce cardiovascular deaths and recurrent heart events over a 140-week period in patients with ATTR-CM. According to Ionis, the study did not achieve its main goal, dealing a setback in a market that has attracted significant attention from drugmakers due to its growth potential. Shares of Ionis fell about 24% on July 9, closing near $64 after trading above $86 the previous day.
The pain didn’t stop there. On July 10, Roche announced it would discontinue its Huntington’s disease collaborations with Ionis, citing a lack of efficacy in the tominersen study and a safety signal in a separate early-stage program. Ionis shares dropped another 8% on the news, bringing the stock to around $58 by the end of the session. According to 24/7 Wall St, these back-to-back developments erased months of gains and left investors reassessing the company’s near-term prospects.
Analyst Response and Market Impact
Wall Street analysts responded quickly, slashing their price targets for Ionis but largely maintaining positive ratings. Jefferies cut its target from $113 to $90, TD Cowen from $108 to $94, Oppenheimer from $110 to $92, BofA Securities from $111 to $90, and Needham from $105 to $86. Most analysts kept their Buy or Outperform ratings, signaling that while the setbacks are significant, they do not view them as fatal to Ionis’s long-term business.
The immediate beneficiaries of Ionis’s misfortune were its competitors. Shares of Alnylam Pharmaceuticals and BridgeBio jumped as the failed Wainua trial reduced near-term competition in the ATTR-CM market. Both companies, along with Pfizer, already market approved therapies for this condition, and the latest developments may give them more room to grow prescriptions, according to Benzinga.
Business Resilience and Next Steps
Despite the recent setbacks, Ionis’s broader business remains intact. Wainua is already approved and generating revenue in more than 20 countries for a separate nerve disorder, and the failed trial was focused on expanding its use into heart disease rather than defending its current market. In the first quarter of 2026, Ionis reported revenue of $246 million and projected full-year revenue between $875 million and $900 million.
Looking ahead, Ionis and AstraZeneca plan to present the full CARDIO-TTRansform dataset at the European Society of Cardiology Congress in August. Investors will be watching closely to see if any patient subgroups showed meaningful benefit, which could influence future regulatory or commercial strategies. Additionally, Ionis expects two regulatory decisions on other drugs before year-end, offering further opportunities to demonstrate the depth of its pipeline beyond Wainua’s heart indication.
For investors, the recent price drop was driven by specific clinical disappointments rather than a collapse of the underlying business. The next few months will be critical as new data and regulatory milestones arrive, potentially resetting expectations for Ionis’s growth trajectory.
According to Ionis’s most recent financial filings, the company ended the first quarter of 2026 with $246 million in revenue and guided for $875 million to $900 million in revenue for the full year. The stock’s five-day decline of nearly 29% followed a period of strong gains earlier in the year, highlighting the outsized impact that clinical trial results can have on biotech valuations.
Biotech investing often involves binary outcomes, where a single trial can dramatically alter a company’s outlook. For Ionis, the failed Wainua trial and Roche’s exit from Huntington’s disease programs underscore the risks inherent in drug development. Investors in this sector should be prepared for sharp swings tied to clinical and regulatory news, and should consider the diversification of a company’s pipeline, the strength of its partnerships, and the competitive landscape when evaluating long-term potential. While Ionis’s recent setbacks are a reminder of these risks, the company’s ongoing revenue streams and upcoming catalysts mean its story is far from over.
